Information:
Error:
ID
44775
Description
Study documentation part: On- Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3
Keywords
Versions (3)
- 8/2/15 8/2/15 -
- 8/6/15 8/6/15 -
- 11/18/21 11/18/21 -
Copyright Holder
Bristol-Myers Squibb
Uploaded on
November 18, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – On- Treatment
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – On- Treatment
Similar models
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – On- Treatment
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Subject number
Item
Subject number:
integer
C1709561 (UMLS CUI-1)
Subject initial
Item
Subject initial:
text
C2986440 (UMLS CUI-1)
Visit date
Item
Visit date:
date
C0011008 (UMLS CUI-1)
C0545082 (UMLS CUI-2)
C0545082 (UMLS CUI-2)